Latest Breaking News On - Eva kalias - Page 3 : comparemela.com
European Commission (EC) grants marketing authorization for AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and olderAGAMREE® is the only approved medication in the European Union (EU) for treating DMD, and the first DMD treatment approved in both the U.S. and EUFirst commercial launch of AGAMREE®, in Germany, expected in Q1-2024 EMA acknowledges safety benefits of AGAMREE® with regards to preserving bone health and maintaining growth compared to standard
United-kingdomIcelandSwitzerlandLiechtensteinPrattelnSwitzerland-generalUnited-statesNorwayGermanySwissAmericaElizabeth-vroom